Skip to main content

Press Releases

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

"The Economic Report" to Feature Kane Biotech Inc.

DEERFIELD BEACH, FLORIDA -- (MARKET WIRE) -- 09/02/08 -- The producers of The Economic Report, are pleased to announce that Kane Biotech Inc. (TSX VENTURE: KNE) will be featured in an upcoming episode on Emerging Developments in Biofilm Technologies as part of the show's Medical Minutes series. This episode will air nationally on Fox Business News and regionally on both CNN & Regional News Networks.

Scientists are finding that one of the ways microbes make us sick is by arranging themselves in very sophisticated communities called biofilms. Bacteria in biofilms like to stick together to everything from our teeth to surgically implanted medical devices. Up to 80 percent of human bacterial infections may involve biofilms and the cost of treating them reaches billions of dollars a year in the United States alone. The problem is that once they have formed, bacteria in biofilms become extremely difficult to treat.

"Once in a biofilm, bacteria can be several orders of magnitude more resistant to antibiotics than their planktonic (free-floating) counterparts," says Dr. Srinivasa Madhyashta, Chief Scientific Officer for Kane Biotech Inc. "Whatever the mechanism of drug resistance, bacteria in biofilms often outlive treatment. A method of long-term prevention of biofilm formation that acts at the level of the bioflim formation is needed."

Kane Biotech is a leader in research and development of technologies and products that prevent and remove bacterial biofilms. Its growing portfolio is based upon leading research and relationships with prominent academic institutions. The company is developing products that address human health issues, including hospital acquired infections related to medical devices, chronic wound healing and novel treatments in the prevention of tooth decay.

The five-minute segment will be filmed on location at the Center for Biofilm Engineering at Montana State University. It will include interviews with the Center's director as well as officials from Kane Biotech Inc.

To learn more about Kane Biotech, please visit and for more information on the Center for Biofilm Engineering, please visit

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Kane Biotech Inc.
Gord Froehlich
President and CEO
(204) 477-7592
(204) 453-1301 (FAX)